Protein A has made monoclonal antibodies (MAbs) highly manufacturable and easier to develop in laboratories. Its use has enabled purification platform approaches, which have been key elements in growth of the MAb market. But in general, protein A columns are too large, which means they either limit the use of prepacked technology, or create a mismatch between a protein A column and downstream operations. Protein A columns also are more prone to bioburden contamination than any other step in a downstream process. The special report Addressing High Demands for Increased Productivity in Downstream Operations focuses on these issues and technologies and innovations that will help companies improve their manufacturing process.

Just fill out the form to view and download the complete eBook.

Get the eBook Now